Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medtronic has received approval from the Japanese Ministry of Health, Labor and Welfare for its Endeavor drug-eluting coronary stent system, clearing the way for the launch of the product in the country.
Subscribe to our email newsletter
Medtronic plans to launch the Endeavor drug-eluting stent (DES) immediately following the authorization of reimbursement which is expected on May 1, 2009. Following the launch in Japan, the Endeavor DES will be commercially available for the treatment of coronary artery disease in every major market in the world, said Medtronic.
The Endeavor DES provides the reassurance of long-term safety and durable efficacy in the treatment of coronary artery disease, claims Medtronic.
Sean Salmon, vice president of Medtronic CardioVascular and general manager of Medtronic’s coronary and peripheral business, said: “The large and growing body of evidence from clinical studies and clinical practice around the world continues to demonstrate the enduring benefits of the Endeavor stent for patients with coronary artery disease. We look forward to bringing these benefits to Japan very soon.”